Peri-Procedural Interruption of Apixaban for Endometrial Biopsy
Apixaban (Eliquis) interruption for endometrial biopsy should be based on the procedure’s bleeding risk and renal function. For gynecologic ultrasound-guided biopsy, apixaban is typically withheld 1–3 days before the procedure depending on renal function, with resumption 1–2 days after the procedure if no bleeding complications occur [1].
Medication Selection Algorithm
The peri-procedural plan for apixaban interruption should follow the bleeding-risk category and renal function [1], [2].
- Low-to-moderate bleeding risk procedures with adequate renal function: direct oral anticoagulant is stopped 1–2 days before the procedure [2].
- Increased bleeding risk associated with impaired renal function: direct oral anticoagulant hold time should be increased beyond the 1–2 day interval used for patients with higher glomerular filtration rate [2].
- Gynecologic oncology ultrasound-guided biopsy: apixaban is withheld 1–3 days before the procedure depending on agent and renal function [1].
Treatment Initiation Thresholds
Hold time for apixaban should be individualized by renal function severity because apixaban clearance varies with kidney function [2].
- If glomerular filtration rate is ≥50 mL/min per 1.73 m² (0.83 mL/s per 1.73 m²), direct oral anticoagulants are stopped 1–2 days before procedures with bleeding risk higher than minimal (low-to-moderate or high bleeding risk) [2].
- If glomerular filtration rate is <50 mL/min per 1.73 m², a longer interruption period is recommended [2].
- For gynecologic ultrasound-guided biopsy, the recommended apixaban hold interval is 1–3 days depending on renal function and procedure context [1].
Resumption Timing After Endometrial Biopsy
Apixaban should be resumed after the procedure once hemostasis is secure and there are no bleeding complications [1], [2].
- For gynecologic biopsy, apixaban is typically resumed 1–2 days after the procedure in the absence of bleeding complications [1].
- For general perioperative DOAC management, direct oral anticoagulants are commonly restarted about 24 hours after surgery when bleeding risk is low or moderate [2].
Common Pitfalls to Avoid
- Resuming apixaban despite procedure-related bleeding increases risk of clinically significant post-procedural bleeding [1].
- Using a shorter hold interval designed for preserved renal function despite impaired renal function increases residual anticoagulant effect at biopsy [2].
Practical Timing Targets (Given “Impaired Renal Function”)
Exact timing requires a creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) value. In the absence of the numeric renal function value, guideline-consistent targets for gynecologic biopsy are as follows:
- Stop apixaban 1–3 days before the endometrial biopsy, using the longer end of the range for more impaired renal function [1].
- Resume apixaban 1–2 days after the biopsy once hemostasis is established and no bleeding complications are present [1].
Targets and Goals of Therapy
The goal of interruption and resumption is minimizing residual anticoagulant effect at the time of endometrial biopsy while restoring therapeutic anticoagulation after hemostasis is achieved [1], [2].